Macquarie Group
MACK

Macquarie Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Macquarie Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,034
Closed -$6K – 2317
2018
Q4 		$6K Buy
+2,034
New +$7.05K ﹤0.01% 2090
2018
Q2 		– Sell
-22,662
Closed -$144K – 2361
2018
Q1 		$144K Sell
22,662
-8,007
-26% -$66.3K ﹤0.01% 1803
2017
Q4 		$247K Buy
30,669
+18,683
+156% +$174K ﹤0.01% 1679
2017
Q3 		$137K Buy
+11,986
New +$126K ﹤0.01% 1849

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Macquarie Group's MACK Position: Q1 2019 in Review

Macquarie Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2019, closing a stake of 2,034 shares — an estimated $6K sold.

Macquarie Group first reported a position in MACK in Q3 2017 and held it in 4 quarters. The position peaked at $247K in Q4 2017. 54 funds tracked by Wall St. Rank hold MACK as of Q1 2019.

  • Macquarie Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 2,034 Merrimack Pharmaceuticals, Inc. shares in Q1 2019, an estimated $6K.
  • Macquarie Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2017 and held it in 4 quarters.
  • Macquarie Group's Merrimack Pharmaceuticals, Inc. position peaked at $247K in Q4 2017.
  • 54 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.